COVID-19 does appear to increase the risk of developing dementia, though the relationship is complex. A large meta-analysis covering more than 26 million participants found that people who had COVID-19 faced a 49% higher risk of new-onset dementia compared to those who never had the infection. That elevated risk persisted for at least two years after infection and was most pronounced in adults over 65.
How Much the Risk Increases
The size of the risk depends on what you compare COVID-19 to. When researchers compared people who had COVID with those who had no infection at all, the risk of new dementia was 65% higher in the COVID group. But when they compared COVID patients to people who had other respiratory infections like the flu, the gap narrowed considerably, with COVID carrying about a 29% higher risk. And when compared specifically to influenza or sepsis, the excess risk disappeared entirely.
That pattern matters. It suggests that severe infections in general are hard on the brain, and COVID-19 may simply be one of the more potent examples. Adults 60 and older who had COVID showed a 1.84-fold increased risk of dementia at 12 months compared to people with no documented infection. Both men and women were affected, with the risk remaining elevated in people over 65 (68% higher than uninfected peers).
What COVID Does to the Brain
Several biological mechanisms help explain how a respiratory virus can threaten long-term brain health. The spike protein on the surface of SARS-CoV-2 can cross the blood-brain barrier, the tightly sealed layer of cells that normally keeps pathogens and toxins out of brain tissue. Once inside the central nervous system, the virus invades microglia, the brain’s resident immune cells, and triggers inflammation.
In animal studies, exposing brain tissue to the spike protein activated the release of inflammatory signaling molecules. Older animals with existing features of Alzheimer’s disease mounted a much stronger inflammatory response than younger ones, releasing more types of inflammatory signals and in greater quantities. This suggests that people who already have early, undetected brain changes may be especially vulnerable to COVID-related damage.
Signs of Alzheimer’s-Related Protein Changes
One of the more concerning findings comes from blood biomarker research published in Nature Medicine. After SARS-CoV-2 infection, older adults showed shifts in proteins closely linked to Alzheimer’s disease. Specifically, they had a reduced ratio of two forms of beta-amyloid (the protein that clumps into plaques in Alzheimer’s brains) and, among more vulnerable individuals, higher levels of phosphorylated tau, another hallmark Alzheimer’s protein.
These biomarker changes weren’t just abstract lab findings. They correlated with brain structural patterns associated with Alzheimer’s disease on imaging, lower cognitive test scores, and poorer overall health ratings. People with pre-existing high blood pressure showed even greater changes in their amyloid levels after infection. The researchers were careful to note that this doesn’t prove COVID causes Alzheimer’s, but it does suggest the infection can accelerate the type of brain pathology that leads there.
Visible Brain Shrinkage on Imaging
MRI studies of COVID patients with cognitive and smell-related symptoms have revealed significant loss of grey matter, the brain tissue responsible for processing information. In one study, 73 out of 138 measured brain regions showed significant shrinkage compared to healthy controls. The most severely affected areas included the hippocampus (critical for forming new memories), the amygdala (involved in emotion and memory), the putamen and caudate nucleus (involved in movement and learning), and the cingulate gyrus and precuneus (regions involved in attention and self-awareness).
Several of these regions overlap with the areas that deteriorate earliest in Alzheimer’s disease, particularly the hippocampus. Cortical thinning was also detected in areas near the top of the brain and in the visual cortex. This kind of widespread tissue loss in a post-infectious context is unusual and helps explain why some people experience persistent cognitive problems after COVID.
Brain Fog vs. Dementia
Not everyone with post-COVID cognitive problems is developing dementia. Many people experience what’s commonly called brain fog: difficulty concentrating, slow thinking, and trouble finding words. The World Health Organization recognizes cognitive dysfunction as a core feature of post-COVID condition and has assigned it a specific diagnostic code (ICD-11 code RA02).
Dementia, by contrast, involves a gradual, progressive loss of cognitive ability severe enough to interfere with daily tasks like managing finances, following conversations, or navigating familiar places. Brain fog after COVID can look similar on the surface, but it often improves over time rather than worsening. The key distinction is trajectory: brain fog tends to plateau or slowly get better, while dementia continues to decline.
That said, the two aren’t entirely separate concerns. Delirium and acute cognitive disruption during illness can accelerate cognitive decline in people who already have underlying vulnerability. A single severe episode of confusion during a COVID hospitalization may speed up deterioration in someone whose brain was already on a path toward dementia.
How Cognitive Recovery Looks Over Time
Longitudinal research tracking COVID survivors for up to 42 months offers a mixed picture. Attention, working memory, and verbal learning and memory all improved progressively over that period. For many people, these domains returned close to normal.
Processing speed and executive functioning told a different story. While both improved, they remained more than one standard deviation below normal averages even three and a half years after infection. Executive functioning covers skills like planning, organizing, and switching between tasks. Processing speed is how quickly you take in and respond to information. These are the kinds of deficits that make everyday life feel harder, even when memory itself is intact. The cognitive burden of long COVID, while not dementia in most cases, is real and lasting for a meaningful number of people.
Who Faces the Highest Risk
Age is the strongest risk factor. The elevated dementia risk after COVID-19 is concentrated in adults over 65, where the hazard ratio reaches 1.68 compared to uninfected peers. People with pre-existing high blood pressure appear particularly vulnerable to the amyloid-related brain changes triggered by infection. Those who already have early, subclinical signs of neurodegeneration, detectable on brain imaging but not yet causing obvious symptoms, show steeper declines in protective proteins and greater increases in harmful ones after COVID.
Severity of the initial infection also plays a role. Hospitalized patients face a greater cognitive burden than those with mild or asymptomatic cases, consistent with the broader pattern that more intense systemic inflammation causes more brain damage. However, even non-hospitalized infections have been linked to measurable biomarker changes in older adults, so mild COVID is not entirely without neurological consequence.